You are here:
26 May 2021 / deal

Gilde Healthcare's Private Equity fund sells majority stake in European CRO/CDMO Symeres to Keensight Capital

Keensight Capital, one of the principal private equity managers dedicated to pan-European Growth Buyout1 investments, has reached an agreement to invest alongside management in Symeres, a leading European drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO).

Gilde Healthcare's Private Equity fund sells majority stake in European CRO/CDMO Symeres to Keensight Capital

According to the terms of the agreement, Keensight Capital will acquire a majority stake in Symeres from the Gilde Healthcare Private Equity fund, a leading European specialist healthcare investor.



OptiGroup AB acquires Koemans Verpakkingen B.V

OptiGroup AB acquires Koemans Verpakkingen B.V

The company will become part of OptiGroup’s Packaging business area and will continue to operate under its current brand. read more
Litigation-Trend-Report

Trend Report - Litigation & Risk Management - Sept. 2021

This trend report provides practical guidance to help mitigate exposure to litigation challenging such transactions. read more
deal-id&t1

LiveStyle sells ID&T to Superstruct Entertainment

Loyens & Loeff advised longstanding client LiveStyle on its sale of ID&T to Superstruct, a portfolio company of Providence Equity. read more